Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11575086 | 0.78 | — | — | |
| SCHEMBL1062632 | 0.78 | — | — | |
| SCHEMBL9495145 | 0.73 | TSHR (0.37) | TSHR | |
| SCHEMBL1688001 | 0.70 | — | — | |
| SCHEMBL1460960 | 0.67 | — | — | |
| SCHEMBL8903116 | 0.67 | — | — | |
| SCHEMBL1533512 | 0.67 | — | — | |
| SCHEMBL4790574 | 0.67 | — | — | |
| SCHEMBL2879089 | 0.67 | — | — | |
| SCHEMBL1416300 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015003146-A1 | BORONIC ACID DERIVATIVES OF RESVERATROL FOR ACTIVATING DEACETYLASE ENZYMES | GEORGETOWN UNIVERSITY (US) | 2015-01-08 | — | — | WO | claimed |
| EP-1644328-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | Aston University (GB) | 2006-04-12 | — | — | EP | claimed |
| WO-2005005387-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | ASTON UNIVERSITY (GB) | 2005-01-20 | — | — | WO | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | claimed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | G. D. SEARLE & CO. (US) | 2004-07-01 | — | — | US | claimed |
| US-20040116486-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | claimed |
| US-6689754-B1 | PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074749-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| JP-2001506611-A | — | — | 2001-05-22 | — | — | JP | claimed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0942902-A2 | NOVEL IMMUNOTHERAPEUTIC IMIDES/AMIDES | CELGENE CORPORATION (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | claimed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0246126-A1 | Benzimidazoles and imidazopyridine sulfone amides, process for their preparation and their use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1987-11-19 | — | — | EP | claimed |
| EP-0080814-B1 | CHROMOGENIC COMPOUNDS | YAMAMOTO KAGAKU GOSEI CO., LTD. (JP) | 1986-10-15 | — | — | EP | claimed |
| EP-0080814-A1 | Chromogenic compounds | YAMAMOTO KAGAKU GOSEI CO., LTD. (JP) | 1983-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | TSHR 3771/4885ALDH1A1 294/4885 |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | ITGB3, ITGAL, ITGB1 | TSHR 3161/4885ALDH1A1 388/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | TSHR 2971/4885ALDH1A1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.